Assessment of Composite Inflammatory Ratios in Juvenile Idiopathic Arthritis and Their Association With Disease Activity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: complete blood count, serum albumin.
- Who it may be relevant to
- Registry conditions: Juvenile Idiopathic Arthritis. Basic parameters: up to 16 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Juvenile Idiopathic Arthritis (JIA) is a prevalent pediatric rheumatic disorder characterized by persistent inflammation of one or more joints in children and adolescents. This chronic condition is a major contributor to both short- and long-term morbidity and functional disability We aim in this study to investigate the role of CAR, PLR, NLR ,systemic inflammatory index (SII ) and NAR ( SII and NAR have never been evaluated before in JIA patients ) as potential markers of disease activity in patients with non-systemic JIA (nsJIA) .
Interventions
- Diagnostic test complete blood count
blood test - Diagnostic test serum albumin
blood test
Primary outcome measures
- possibility to use crp to albumin level as novel biomarker to predict disease activity in juvenile 0idiopathic arthritis [Time frame: 6 months]
- possibility to detect systemic inflammatory index and its relation to disease activity and risk of flare in juvenile idiopathic arthritis [Time frame: 6 months]
- assessment of activity of disease according to JDAS SCORE [Time frame: 6 months]
- assessment of neutrophils to albumin ratio and its relation to JDAS score activity score [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
\-
1\. Patients who classified JIA according to International League of Associations for Rheumatology ILAR criteria on treatment with exclusion of systemic JIA.
2\. Patients with disease duration more than 6 months. 3. Age below 16 years old. 4. Patient cooperative and can answer questions. 5. Patients who are able and willing to give written informed consent or their parents/guardians
Exclusion criteria
- 1\. Systemic JIA. 2. Patients with other autoimmune or autoinflammatory diseases, immunodeficiencies, hematologic conditions, malignances and infectious disease at enrollment time or in the previous 2 weeks.
Patients who are not able and willing to give written informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Huang JL. New advances in juvenile idiopathic arthritis. Chang Gung Med J. 2012 Jan-Feb;35(1):1-14. doi: 10.4103/2319-4170.106171. PMID 22483423
- Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011 Jun 18;377(9783):2138-49. doi: 10.1016/S0140-6736(11)60244-4. PMID 21684384
- Milovanovic M, Nilsson E, Jaremo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta. 2004 May;343(1-2):237-40. doi: 10.1016/j.cccn.2003.12.030. PMID 15115702
- Erre GL, Paliogiannis P, Castagna F, Mangoni AA, Carru C, Passiu G, Zinellu A. Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest. 2019 Jan;49(1):e13037. doi: 10.1111/eci.13037. Epub 2018 Nov 6. PMID 30316204
Identifiers
NCT: NCT07083466 · Soh-Med-25-6-6MS